MIGUEL CASTELLANOS: Open Payments
NPI 1972218261 · ANAHEIM, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$812 in 44 payments from 10 companies in 2025. Trend: 2023 $1,588 · 2024 $1,569 · 2025 $812
Food & beverage: $812
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $271 |
| Janssen Pharmaceuticals, Inc | 7 | $157 |
| Otsuka America Pharmaceutical, Inc. | 7 | $146 |
| Vanda Pharmaceuticals Inc. | 4 | $87 |
| ABBVIE INC. | 2 | $33 |
| Lundbeck LLC | 1 | $28 |
| Corium, LLC | 3 | $28 |
| Biogen, Inc. | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: CAPLYTA, REXULTI, SPRAVATO, FANAPT, INVEGA SUSTENNA, ABILIFY MAINTENA, VRAYLAR, Azstarys.
Industry payments across CA — which companies pay providers there.
